Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT01652079 |
Title | CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer |
Recruitment | Completed |
Gender | female |
Phase | Phase II |
Variant Requirements | No |
Sponsors | Massachusetts General Hospital |
Indications | |
Therapies | |
Age Groups: | adult |
Covered Countries | USA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States | Details | |
Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02115 | United States | Details | |
Brigham and Women's Hospital | Boston | Massachusetts | 02215 | United States | Details | |
Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | United States | Details |